<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331341</url>
  </required_header>
  <id_info>
    <org_study_id>9805</org_study_id>
    <secondary_id>NCI-2017-01718</secondary_id>
    <secondary_id>9805</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG1001581</secondary_id>
    <nct_id>NCT03331341</nct_id>
  </id_info>
  <brief_title>Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma</brief_title>
  <official_title>A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine, and Dacarbazine (APVD) for Patients With Untreated Classical Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects of doxorubicin hydrochloride, pembrolizumab,&#xD;
      vinblastine, and dacarbazine in treating patients with classical Hodgkin lymphoma. Drugs used&#xD;
      in chemotherapy, such as doxorubicin hydrochloride, vinblastine, and dacarbazine, work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading. Immunotherapy with pembrolizumab, may&#xD;
      induce changes in body's immune system and may interfere with the ability of tumor cells to&#xD;
      grow and spread. Giving doxorubicin hydrochloride, pembrolizumab, vinblastine, and&#xD;
      dacarbazine may work better in treating classical Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      PART A: Patients receive doxorubicin hydrochloride intravenously (IV), vinblastine IV, and&#xD;
      dacarbazine IV on days 1 and 15. Patients also receive pembrolizumab IV over 30 minutes on&#xD;
      days 1 and 22 of cycle 1 and on day 15 of cycle 2. Treatment repeats every 28 days for up to&#xD;
      2 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PART B: Patients receive doxorubicin hydrochloride IV, vinblastine IV, dacarbazine IV, and&#xD;
      pembrolizumab IV as in part A, but undergo a total of 6 treatment cycles.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days and then up to 5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PART A: Number of participants who complete of 2 cycles of adriamycin, pembrolizumab, vinblastine and dacarbazine (APVD)</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 28 days)</time_frame>
    <description>Number of participants who complete 2 cycles of treatment without a dose delay of &gt;3 weeks. Toxicity leading to dose delay will be assessed using CTCAE v5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PART B: Event Free Survival at 1 year</measure>
    <time_frame>At the end of 1 year after completing 2 cycles of treatment (each cycle is 28 days)</time_frame>
    <description>Number of participants who are event free at 1 year. An event is defined as progression, biopsy proven recurrence, initiation of next line of chemotherapy, or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) 2 negative (Deauville score 1-3) patients after 2 cycles of APVD</measure>
    <time_frame>After 2 cycles (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (APVD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PART A: Patients receive doxorubicin hydrochloride intravenously (IV), vinblastine IV, and dacarbazine IV on days 1 and 15. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of cycle 1 and on day 15 of cycle 2. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
PART B: Patients receive doxorubicin hydrochloride IV, vinblastine IV, dacarbazine IV, and pembrolizumab IV as in part A, but undergo a total of 6 treatment cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (APVD)</arm_group_label>
    <other_name>4-(Dimethyltriazeno)imidazole-5-carboxamide</other_name>
    <other_name>5-(Dimethyltriazeno)imidazole-4-carboxamide</other_name>
    <other_name>Asercit</other_name>
    <other_name>Biocarbazine</other_name>
    <other_name>Dacarbazina</other_name>
    <other_name>Dacarbazina Almirall</other_name>
    <other_name>Dacarbazine - DTIC</other_name>
    <other_name>Dacatic</other_name>
    <other_name>Dakarbazin</other_name>
    <other_name>Deticene</other_name>
    <other_name>Detimedac</other_name>
    <other_name>DIC</other_name>
    <other_name>Dimethyl (triazeno) imidazolecarboxamide</other_name>
    <other_name>Dimethyl Triazeno Imidazol Carboxamide</other_name>
    <other_name>Dimethyl Triazeno Imidazole Carboxamide</other_name>
    <other_name>dimethyl-triazeno-imidazole carboxamide</other_name>
    <other_name>Dimethyl-triazeno-imidazole-carboximide</other_name>
    <other_name>DTIC</other_name>
    <other_name>DTIC-Dome</other_name>
    <other_name>Fauldetic</other_name>
    <other_name>Imidazole Carboxamide</other_name>
    <other_name>Imidazole Carboxamide Dimethyltriazeno</other_name>
    <other_name>WR-139007</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (APVD)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (APVD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (APVD)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (APVD)</arm_group_label>
    <other_name>Vincaleucoblastine</other_name>
    <other_name>VLB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have cHL that has not been previously treated&#xD;
&#xD;
               -  Part A: Any stage&#xD;
&#xD;
               -  Part B: Must be stage 3 or 4&#xD;
&#xD;
          -  Patients must be appropriate candidates for at least 2 cycles of doxorubicin&#xD;
             hydrochloride (adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) (6 cycles&#xD;
             for Part B patients) or doxorubicin hydrochloride, vinblastine, dacarbazine (AVD)&#xD;
             (this could include patients ranging from favorable risk early stage disease to poor&#xD;
             prognosis advanced stage disease)&#xD;
&#xD;
          -  Patients must have measurable FDG-avid disease defined by standard criteria (Lugano&#xD;
             2014) and a minimum of 1.0 cm in diameter&#xD;
&#xD;
          -  Patients should not have evidence of active central nervous system lymphoma&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0 or 1&#xD;
&#xD;
          -  Patients must have a left ventricular ejection (LVEF) &gt;= 50% within 56 days of&#xD;
             enrollment&#xD;
&#xD;
          -  Patients must have adequate labs within 10 days of treatment unless cytopenia is&#xD;
             thought to be due to underlying disease&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/mm^3 (without transfusion or growth factor&#xD;
             support)&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mm^3 (without transfusion or growth factor support)&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 mg/dl or creatinine clearance greater than 60/ ml per minute by&#xD;
             the following formula (all tests must be performed within 28 days prior to&#xD;
             registration)&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times upper limit of normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) &lt; 2.5 times upper limit of normal&#xD;
&#xD;
          -  All patients must be informed of the investigational nature of this study and have&#xD;
             given written consent in accordance with institutional and federal guidelines&#xD;
&#xD;
          -  Patients must be anticipated to complete at least 2 cycles of chemotherapy&#xD;
&#xD;
          -  Male subjects should agree to use an adequate method of barrier contraception starting&#xD;
             with the first dose of study therapy through 120 days after the last dose of study&#xD;
             therapy&#xD;
&#xD;
          -  Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to receiving the first dose of study medication; if&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required&#xD;
&#xD;
          -  Female subjects of childbearing potential should be willing to use 2 methods of birth&#xD;
             control or be surgically sterile, or abstain from heterosexual activity for the course&#xD;
             of the study through 120 days after the last dose of study medication; subjects of&#xD;
             childbearing potential are those who have not been surgically sterilized or have not&#xD;
             been free from menses for &gt; 1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients known positive for human immunodeficiency virus (HIV), or infectious&#xD;
             hepatitis type B or C&#xD;
&#xD;
          -  Pregnant or nursing women; men or women of reproductive potential may not participate&#xD;
             unless they have agreed to use an effective contraceptive method&#xD;
&#xD;
          -  Patients with other prior malignancies except for adequately treated basal cell&#xD;
             carcinoma, squamous cell carcinoma of the skin, breast or cervical cancer in situ, or&#xD;
             other cancer from which the patient has been disease-free for 5 years or greater,&#xD;
             unless approved by the protocol chair or co-chair&#xD;
&#xD;
          -  Patients who have other medical conditions that would contraindicate treatment with&#xD;
             aggressive chemotherapy (including active infection, uncontrolled hypertension,&#xD;
             congestive heart failure, unstable angina pectoris, or myocardial infarction within&#xD;
             the past 6 months, uncontrolled arrhythmia, severe pulmonary disease or requirement of&#xD;
             supplemental oxygen)&#xD;
&#xD;
          -  Active ischemic heart disease or congestive heart failure&#xD;
&#xD;
          -  Concurrent use of other anti-cancer agents or experimental treatments&#xD;
&#xD;
          -  Known current or prior autoimmune disease with the exception of vitiligo&#xD;
&#xD;
          -  Active or prior history of pneumonitis/interstitial lung disease that required&#xD;
             corticosteroids&#xD;
&#xD;
          -  Current use of supplemental oxygen&#xD;
&#xD;
          -  Is known to have received a live vaccine or live-attenuated vaccine within 30 days&#xD;
             prior to the first dose of trial treatment. Administration of killed vaccines is&#xD;
             allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Lynch</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan Lynch</last_name>
    <phone>206-606-1739</phone>
    <email>rclynch@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Lynch</last_name>
      <phone>206-606-1739</phone>
      <email>rclynch@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Lynch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Imidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

